ClinicalTrialsFinder

HER2-negative Breast Cancer Clinical Trials in Barcelona, Catalonia

1 recruitingBarcelona, Catalonia, Spain

Showing 1–1 of 1 trials

Recruiting
Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432